Your Article Summary
See Latest ArticlesImpact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab
Digestive Diseases and Sciences, 06/22/09
Moss AC et al. - The combination of maintenance infliximab and an immunomodulator produced modest improvements in outcomes beyond maintenance infliximab alone in this cohort.
Alan C. Moss, 06/22/09
| Our study found that combining azathioprine or 6MP with infliximab (combination therapy) produced differences in remission rates that were significant at 1 year, but not 2 or 5 year end-points. Theses results are similar to post-hoc analyses of the maintenance studies of infliximab, adalimumab and certolizumab; patients on combination therapy had similar remission rates to those on monotherapy with an anti-TNF. These populations, and ours, are different to those enrolled in the recent SONIC study. The patients enrolled in SONIC had a shorter duration of disease, and were all immunomodulator-naive. Thus one can speculate that intervention with combination therapy early in the course of Crohn's disease produces better results than using this approach later on. Whether using combination therapy in this population will result in any higher risk for serious infections or lymphoma is currently unknown. |
Related Articles
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Relevance Score: 92%
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçets disease refractory to standard immunosuppressive drugs
Rheumatology International, 10/30/09
Relevance Score: 90%
Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09
Relevance Score: 88%
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09
Relevance Score: 88%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 87%
Today in Inflammatory Bowel Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Insights into IBD pathogenesis
Current Gastroenterology Reports, 12/09/09
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohns disease)
Current Gastroenterology Reports, 12/09/09
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/09/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/09/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/09/09
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/09/09